Parallax Volatility Advisers, L.P. Bluebird Bio, Inc. Transaction History

Parallax Volatility Advisers, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $37,540 - $52,078	-495 Reduced 76.15%	155 $20,000
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $173,150 - $279,743	-2,687 Reduced 80.52%	650 $102,000
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $4,018 - $6,341	-68 Reduced 2.0%	3,337 $331,000
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $167,056 - $220,881	1,880 Added 123.28%	3,405 $497,000
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $150,257 - $192,405	1,508 Added 8870.59%	1,525 $239,000
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $789,162 - $1.13 Million	-7,459 Reduced 99.77%	17 $3,000
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $607,425 - $977,113	7,476	7,476 $1.33 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.